HIMS, Super Bowl and Hers

Hims & Hers Health (NYSE: HIMS) is surging today. The stock is up 19%, and this is part of a broader 482.5% rally in the past year that has carried this telehealth company to nosebleed levels. Here’s ...
Compounded weight-loss medications such as those promoted in the Hims & Hers commercial aren’t approved by the Food and Drug ...
Hims & Hers has shown impressive revenue growth, accelerating from 46% to 77%. Read why I downgrade HIMS stock from buy to ...
Hims & Hers, a San Francisco-headquartered telehealth company, ran its controversial Super Bowl commercial despite multiple ...
BJP MLA Vijender Gupta on Thursday urged Lieutenant Governor VK Saxena to implement the PM-ABHIM and the HIMS schemes in Delhi to help revive the city’s struggling public healthcare system. In a ...
Hims & Hers' future growth is expected from personalized solutions, with potential to expand the subscriber base by millions.
The goal is to either have the put expire worthless and keep the premium, or to be assigned and acquire the stock below the ...
Telehealth company Hims & Hers stirred up controversy by debuting a 2025 Super Bowl ad touting the benefits of its ...